Journal
DRUGS
Volume 79, Issue 15, Pages 1719-1725Publisher
ADIS INT LTD
DOI: 10.1007/s40265-019-01205-x
Keywords
-
Categories
Ask authors/readers for more resources
Fedratinib (INREBIC (R)) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Phase III clinical development for myelofibrosis is ongoing worldwide. This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available